Candidemia Market Analysis
Candidemia is the most common fungal bloodstream infection, and possibly the fourth most common all-type bloodstream infection seen in the intensive care unit setting. The incidence of Candida bloodstream infection is bimodal, with the elderly and very young having the highest risk of any population for suffering from this disease.
Common symptoms of candidemia include fever and chills that do not improve with antibiotics. The infection can also cause septic shock and therefore may include symptoms such as low blood pressure, fast heart rate, and rapid breathing.
As per the study titled “National Burden of Candidemia, United States, 2017” by Tsay et al. (2018), suggests that an estimated 23,000 candidemia cases occurred in the United States in 2017. Overall estimated incidence was calculated to be 7.0 per 100,000 persons, with elevated rates in adults ≥65 years (20.3 per 100,000), males (8.0 per 100,000).
For more details on Candidemia Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/candidemia-market
Adult-Onset Still Disease Market Analysis
Adult Onset Still disease (AOSD) is a rare inflammatory arthritis that mainly starts in adulthood and affects the entire body. The symptoms, progression and severity of the disease vary significantly from person to person.
Some of the most common symptoms of Adult-Onset Still's Disease includes a daily fever, sore throat, salmon-pink rash, achy and swollen joints (especially knees and wrists), muscular pain, abdominal pain, inflamed or swollen lymph nodes, and other symptoms that are associated with systemic inflammatory disease.
It is observed that Adult onset Still’s disease affects men and women in equal numbers. Adult-Onset Still's Disease mainly affects young adults aged between 16-35. Due to highly variable symptoms the disease remains undiagnosed or misdiagnosed.
Some of the key companies involved in developing therapies for Adult-Onset Still Disease include Novartis Pharmaceuticals, AB2 Bio, Hikma Pharmaceuticals, Teva Pharmaceutical, Swedish Orphan Biovitrum, Jubilant Life Sciences, Mylan N.V., and many others.
For more details on Adult-Onset Still Disease Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/adult-onset-still-disease-market
Lenegre’s disease Market Analysis
Lenegre’s disease is an progressive, fibrotic, sclerodegenerative affliction of the cardiac conduction system that can affect middle-aged people. Lenegre's disease may result in slow progression to complete heart block and hereditary is thought to be the one of the reasons for its occurrence. Lenegre’s diseases can cause right bundle branch block and left anterior hemiblock without other cardiac abnormalities, which can further lead to complete heart block.
The Lenegre’s disease Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Lenegre’s disease Market, historical and forecasted epidemiology, the pipeline insight as well as the Lenegre’s disease market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
For more details on Lenegre’s disease Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/lenegres-disease-market
Cardiovascular Calcification Market Analysis
Cardiovascular calcification is the leading health disorder that leads to the passive degenerative process mainly occurring due to deterioration of tissues caused by the stress and strain of cardiac function. It is observed that it is highly prevalent in patients with chronic kidney disease and is predictive of cardiovascular disease (CVD).
Cardiovascular calcification is triggered by chronic inflammatory disorders such as chronic kidney disease (CKD), type 2 diabetes (T2D), and atherosclerosis that are associated with high prevalence of morbidity and mortality. As of now there are no drug therapies against cardiovascular calcification, the only treatment option is surgery. Some of the risk factors associated with Cardiovascular Calcification includes age, sex, pulse pressure, number of pack-years of smoking, systolic blood pressure, diabetes mellitus, waist circumference, kidney function and many others.
DelveInsight's "Cardiovascular Calcification Market Insights, Epidemiology, and Market Forecast 2030" reports deliver an in-depth understanding of the Cardiovascular Calcification Market, historical and forecasted epidemiology, the pipeline insight as well as the Cardiovascular Calcification market size and shares analysis in the seven major markets (7MM) (i.e. the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom) and Japan.
For more details on Cardiovascular Calcification Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/cardiovascular-calcification-market
Opportunities In Digital Healthcare In The Middle East
Over the past few to deliver the best-class healthcare services to its citizens, the MENA region countries have adopted several digital healthcare technologies. The digitisation of healthcare has helped the countries in monitoring the disease trends, recording compliance to chronic patients to treatment regimens, and tracking the improvements in recovery.
Digital Healthcare technologies have significantly transformed the healthcare landscape in the region, and the regional countries are moving at par with the western countries in terms of the digital healthcare ecosystem. Today the Middle East and North Africa region countries (MENA) offer lucrative opportunities to pharma and biotech players as well as to the tech companies in the healthcare domain.
To read more about the Digital Healthcare Ecosystem in the Middle East, visit: https://duphat.ae/Digital-Healthcare-Ecosystem-in-the-Middle-East
Malignant Pleural Mesothelioma (MPM) Market
In 2017, the therapeutic market of Malignant Pleural Mesothelioma in the seven major markets (i.e the United States, EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan) was USD 290 million.
The total incident cases of Malignant Pleural Mesothelioma in the 7MM was 11,431 in 2017. The incident cases of Malignant Pleural Mesothelioma in the United Kingdom and the United States were found to be 2,495 and 2,627 respectively.
Some of the key companies in the Malignant Pleural Mesothelioma (MPM) Market include Trizell, AstraZeneca, Hoffmann-La Roche, Amphera BV, Polaris Pharmaceuticals, Sellas Life Sciences Group, Momotaro-Gene, PharmaMar, Boehringer Ingelheim Limited, Pfizer, Merck KGaA, Sumitomo Dainippon Pharma, Bayer, ImmunoGen, MorphoSys, TCR2 Therapeutics, Kissei Pharmaceutical, Targovax, Atara Biotherapeutics, Bellicum Pharmaceuticals, Takeda and many others.
For more details on Malignant Pleural Mesothelioma Market, visit: https://www.delveinsight.com/report-store/malignant-pleural-mesothelioma-market
Thymus Cancer Market Analysis
Thymus Cancer is a cancer that starts in the thymus. It is of two types namely thymoma and thymic carcinoma and are quite rare. The Thymus Cancer develops when cancer cells form on the outside surface of the thymus and the exact cause is not known. Thymus Cancer can cause symptoms such as breathing difficulties, weight loss, cough (which may bring up bloody sputum), chest pain, trouble swallowing, loss of appetite, and others. The age and ethnicity are two major risk factors for Thymus Cancer.
As per the American Cancer Society, thymus Cancer occurs at a rate of 1.5 cases for every million people each year in the United States (i.e around 400 cases per year). About 4 out of 10 people with thymomas have no symptoms when their tumor is found. Similarly, as per the American Society of Clinical Oncology (ASCO), most tumors that begin in the thymus are thymoma, but overall, thymoma is uncommon. Less than 1 person out of 1.5 million people develops thymoma.
For more details on Thymus Cancer Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/thymus-cancer-market
Substance (Drug) Abuse Market Analysis
Substance use disorder (SUD), also called Drug addiction, is a condition when a person’s use of alcohol and/or drug substances leads to impairment, such as health problems, disability or problems at work, school or home. Addiction represents the most severe form of this disorder.
According to the American Addiction Centers, in 2017, approximately four percent of the American adolescent population age 12–17 suffered from a substance use disorder. About 1.8% of adolescents had an alcohol use disorder, and about three percent of this population suffered from an illicit drug use disorder. Similarly, as per the study conducted by Polak et al., (2015), SUD belongs to the class of externalizing behaviors that are generally more common among men than women.
For more details on Substance (Drug) Abuse Market Insights, Epidemiology, and Pipeline Analysis visit:
https://www.delveinsight.com/report-store/substance-drug-abuse-market
Sinusitis Market Analysis
Sinusitis is swelling of the sinuses mainly caused by a cold or allergies. Sinusitis is common and it may resolve on its own within 2 to 3 weeks. Some of the common symptoms of Sinusitis include runny nose, stuffy nose, facial tenderness, sinus headache, sore throat, cough, bad breath, fever, and feeling of nasal stuffiness.
As per the Graham Worrall et al. approximately 0.5% of all upper respiratory tract infections are complicated by sinusitis; the incidence of acute sinusitis ranges from 15 to 40 episodes per 1000 patients per year, depending on the setting.
As per the CDC, in the United States (in 2018) nearly 28.9 million adults are diagnosed with sinusitis, which is around 11.6% percent of the adult population.
For more details on Sinusitis Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/sinusitis-market
Relapsing Multiple Sclerosis (RMS) Market Analysis
Multiple Sclerosis is an unpredictable, autoimmune disease that affects the central nervous system. In Multiple Sclerosis, the body’s immune system produces cells and proteins (antibodies) that attack the fatty substance, myelin, which is responsible for protecting the nerve fibres.
According to the revised McDonald Criteria, Multiple Sclerosis Relapse is defined as a “patient-reported or objectively observed event typical of an acute inflammatory demyelinating event in the central nervous system, current or historical, with the duration of at least 24 hours in the absence of fever or infection.”
Some of the key companies in the Relapsing Multiple Sclerosis market include Novartis, Teva Pharmaceuticals, Merck, TG Therapeutics, Sanofi and many others.
For more details on Relapsing Multiple Sclerosis (RMS) Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/relapsing-multiple-sclerosis-rms-market
Peptic Ulcers Market Analysis
Peptic Ulcers are sores, mainly developed on the inside lining of the stomach, lower oesophagus, and the upper portion of the small intestine.It is developed due to bacterium Helicobacter pylori (H. pylori) and erosion from stomach acids.
As per the CDC, an estimated 25 million persons in the United States have had peptic ulcer disease (PUD) during their lifetimes. In the United States, nearly 30 to 40 percent of people get an H. pylori infection. In most cases, the infection remains dormant, or quiet without signs or symptoms, for years. It is observed that most people get an H. pylori infection as a child.
For more details on Peptic Ulcers Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/peptic-ulcers-market
Brain Hemorrhage Market Analysis
Brain haemorrhage or “brain bleed” is a type of stroke which can cause brain damage and it can be life-threatening also. It mainly results due to bleeding between the brain tissue and skull or within the brain tissue itself.
As per the stroke association, in the UK, around 15% of strokes are hemorrhagic (due to a bleed), and about 85% are ischaemic (due to a blockage to the blood supply in the brain). Similarly, as per the Headway UK, in 2016-17, there were 348,453 UK admissions to hospital with acquired brain injury. That is 531 admissions per 100,000 of the population.
For more details on Brain Hemorrhage Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/brain-hemorrhage-market
Asthma Market Share Analysis
Asthma is a chronic lung disease, which makes breathing difficult. When the symptoms suddenly get worse it results in an asthma attack. As of now, there's no cure for asthma, however, with the proper treatment plan its symptoms can easily control. In some cases, it can make trouble while talking or doing physical activities.
As per the WHO, It was estimated that more than 339 million people had Asthma globally in 2016. It is a common disease among children. While, in the United States, more than 25 million people have asthma. Which is nearly equal to the 7.7 per cent of adults and 8.4 percent of children.
For more details on Asthma Market Insights, Epidemiology, and Pipeline Analysis, visit:
https://www.delveinsight.com/report-store/asthma-market
Vasomotor Symptoms (Hot Flashes/Night Sweats) Market Analysis
Vasomotor Symptoms (VMS) are one of the major symptoms of menopause that principally include hot flashes (HF) and night sweats (NS) during menopause and occurs in the majority of women across the globe. A woman with VMS experiences abundant heat accompanied by sweating and flushing, especially around head, neck, chest, and upper back region. VMS results from temperature dysfunction that occurs due to changes in gonadal hormones.
The total prevalent population of Vasomotor Symptoms associated with post menopause in 7MM countries was 41,096,968 in 2017. The prevalent population of Hot Flashes Associated with menopause in 7MM countries is expected to increase.
Among the European 5 countries, Germany had the highest prevalent population of Vasomotor Symptoms, followed by France. On the other hand, Spain had the lowest prevalent population of Vasomotor Symptoms.
Among the 7MM, the US accounts for the 61% USD of the overall market size of Hot Flashes associated
with Post-Menopause in 2017.
For more details on Vasomotor Symptoms (Hot Flashes/Night Sweats) Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/vasomotor-symptoms-market
Acute Respiratory Distress Syndrome (ARDS) Market Analysis
Acute respiratory distress syndrome (ARDS) is a rapidly progressive disease occurring in critically ill patients. The major complication in ARDS is marked by leakage of fluid into the lungs, making breathing difficult or impossible.
Out of total COVID-19 cases, the patients who are critically ill—very few and ranging from 1% to 4%—constitute the potential pool for ARDS.
The total incident population of ARDS in the 7MM was 799,872 in 2017.The incidence of ARDS in the United States was estimated to be 495,655 cases in 2017.
The United States showed the highest incident population of ARDS, as compared to EU5, and Japan. The US accounts for nearly 62% of total cases, for ARDS, in the 7MM countries.
For more details on Acute Respiratory Distress Syndrome (ARDS) Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/acute-respiratory-distress-syndrome-ards-market
Acute On Chronic Liver Failure (ACLF) Market Analysis
Acute-on-chronic liver failure (ACLF) is a recently recognised syndrome in cirrhosis characterised by acute decompensation (AD), organ failure(s), and high short-term mortality. Type-A ACLF is an acute worsening of liver function in a patient with chronic liver disease.
As per Delveinsight estimates, the total population of Acute-on-Chronic Liver Failure (ACLF) in 7 MM were found to be 60,521 in 2017. Germany accounted for the maximum cases which were 17,100 in 2017.
Japan accounted for 3,720 cases Acute-on-Chronic Liver Failure (ACLF) in 2017.
For more details on Acute On Chronic Liver Failure (ACLF) Market Insights, Epidemiology, and Pipeline Analysis, visit: https://www.delveinsight.com/report-store/acute-on-chronic-liver-failure-aclf-market
Neurodegenerative Diseases affect millions of people worldwide. Neurodegenerative Diseases comprises a wide range of diseases such as Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, Spinal muscular atrophy, amyotrophic lateral sclerosis, Multiple sclerosis, frontotemporal dementia, and the spinocerebellar ataxias. Among all the diseases Alzheimer’s is the most commonly prevalent neurodegenerative disorder.
Early diagnosis is crucial to treat the disease and improve patient outcomes.
To date, there is no cure for neurodegenerative diseases and they continue to represent one of the biggest therapeutic challenges.
To tackle the burden of neurodegenerative disorders, worldwide a significant number of programs and initiatives are going on by health bodies and governments to create awareness and education about the neurodegenerative diseases.
For more detailed information on the Growing Burden Of Neurodegenerative Disorders visit:
https://www.delveinsight.com/blog/the-growing-burden-of-neurodegenerative-disorders/
In 2017, the Epidermolysis Bullosa market size in the seven major markets (i.e the United States, EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan) was USD 2,283.40 million, which is expected to increase during the forecast period.
Epidermolysis Bullosa is a cause of significant morbidity and mortality among the affected individuals. It is observed that Epidermolysis Bullosa affects around 1 in 30,000 to 50,000 people. In the seven major markets, total Epidermolysis bullosa prevalent population was 41,509 in 2017.
Worldwide, several pharmaceutical and biotechnology companies such as Fibrocell Science, Castle Creek Pharmaceuticals, RegeneRx Biopharmaceuticals, Amryt Pharma, Abeona Therapeutics, Krystal Biotech, Shionogi, among others are diligently working towards the development of novel treatment therapies for Epidermolysis bullosa.
For more details, visit: https://www.delveinsight.com/blog/epidermolysis-bullosa-market/
In 2017, the Down Syndrome market size in the seven major markets was USD 662.9 million, which is expected to increase during the forecast period. The total diagnosed Down syndrome prevalent population in the seven major market countries ( (i.e the United States, EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan.) was 699,750 in 2017.
The absence of approved products in the Down Syndrome market makes the treatment process more complex, and the disease is associated with numerous health problems and high healthcare costs. However, worldwide many companies are exploring various drugs to find efficient therapy for the treatment of Down syndrome, some of the key companies include AC Immune, Annovis Bio, Alzheon, Balance Therapeutics, OPKO Health, Transition Therapeutics, and many others.
For more details, visit: https://www.delveinsight.com/blog/down-syndrome-market-prevalence/
Artificial Intelligence In Healthcare
Artificial Intelligence (AI) is making its way in almost every sector and healthcare is no exception to it.
Today, AI is in use for some initial healthcare purposes such as detection of disease, drug development, delivery of health services and administration, management of chronic disease, and many others.
However, there are some issues and challenges such as data privacy and security, high costs of creation and maintenance and lack of standard rule and regulation which makes its implementation difficult.
To get an early gain and competitive advantage some of the key companies worldwide such as Caption Health, IBM Watson Health, Oncora Medical, Cloud MedX Health, Babylon Health, Corti, and many others are involved in developing AI-based healthcare-based products and solutions.
Looking at the potential future applications, in the coming years, AI is expected to significantly transform the healthcare Industry by ensuring healthier and longer lives for human beings.
For more details on Artificial Intelligence In Healthcare, visit: https://www.delveinsight.com/blog/artificial-intelligence-in-healthcare/
Joined Feb 2020
